RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.
about
Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistanceNEK2 mediates ALDH1A1-dependent drug resistance in multiple myelomaNew role for granulocyte colony-stimulating factor-induced extracellular signal-regulated kinase 1/2 in histone modification and retinoic acid receptor α recruitment to gene promoters: relevance to acute promyelocytic leukemia cell differentiation.Progress in myeloma stem cellsNetwork analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations.Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.RARα2 expression confers myeloma stem cell featuresProteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cellsTherapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Multidrug resistance strength of the novel multidrug resistance gene HA117: compared with MRP1.MicroRNA-936 induces cell cycle arrest and inhibits glioma cell proliferation by targeting CKS1.
P2860
Q33636104-EAD5BCBF-9B6C-427D-AAAD-225848E5DBC3Q34175179-6DBD6639-E101-4B33-9D30-B48E5D44A11EQ35067960-C6C55F8C-53E8-416E-89A3-9B9C8AE5EBDEQ35102049-379B095F-B200-4F0F-B743-5D2A5252E8BAQ35824980-A754571A-6019-4D96-A55F-37881B658F9FQ35869292-F04AC645-B8C2-46C1-B810-D9E8E4FEB891Q37006888-ECC37BEA-806A-45A2-87B6-C84E80BE52F5Q37113087-828F78F6-5109-4109-BA6E-8855918BC515Q37746021-20378FAF-BF6B-46C5-B29A-27B5DD0139A3Q38758034-35C7C840-3741-45C5-B2A2-2C187A61EF4BQ38874309-1A523120-48B3-4949-B19F-893E29DFE05FQ39679547-26740378-2ADD-42D6-BC7E-B521C6841295Q47095695-46B3C5BF-C542-43D6-98CA-8D975A47D2BF
P2860
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RARalpha2 expression is associ ...... of ATRA treatment in myeloma.
@en
RARalpha2 expression is associ ...... of ATRA treatment in myeloma.
@nl
type
label
RARalpha2 expression is associ ...... of ATRA treatment in myeloma.
@en
RARalpha2 expression is associ ...... of ATRA treatment in myeloma.
@nl
prefLabel
RARalpha2 expression is associ ...... of ATRA treatment in myeloma.
@en
RARalpha2 expression is associ ...... of ATRA treatment in myeloma.
@nl
P2093
P2860
P1433
P1476
RARalpha2 expression is associ ...... of ATRA treatment in myeloma.
@en
P2093
Fenghuang Zhan
Guido Tricot
Hongwei Xu
John D Shaughnessy
Siqing Wang
Zhaoyang Zeng
P2860
P304
P356
10.1182/BLOOD-2008-12-194126
P407
P577
2009-05-20T00:00:00Z